Lv4
436 积分 2024-01-07 加入
Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia
27天前
已完结
Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b/2 trial
27天前
已完结
Comparison of venetoclax and ivosidenib/enasidenib for unfit newly diagnosed patients with acute myeloid leukemia and IDH1/2 mutation: a network meta-analysis
27天前
已完结
Mutation spectrum of FLT3 and significance of non-canonical FLT3 mutations in haematological malignancy
1个月前
已完结
Mapping AML heterogeneity - multi-cohort transcriptomic analysis identifies novel clusters and divergent ex-vivo drug responses
1个月前
已完结
Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice
1个月前
已完结
Venetoclax plus azacitidine in relapsed or refractory T-cell acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 trial
1个月前
已完结
The Clinical and Molecular Characteristics of FLT3 Mutations in Chinese De Novo Adolescent and Adult Acute Lymphoblastic Leukemia Patients
1个月前
已完结
The Application of Personalized Conditioning Regimens in Relapsed/Refractory Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation
3个月前
已完结
Quantification of the FLT3 internal tandem duplication is a reliable marker for monitoring measurable residual disease in acute myeloid leukemia with FLT3-ITD mutations
3个月前
已完结
皖公网安备34019202002308
